Amycretin (Zenagamtide)
Also known as: Zenagamtide, Amycretin
Unimolecular GLP-1 and amylin receptor co-agonist (also calcitonin receptor agonist); incretin-based peptide therapeutic
What it is
Amycretin is an investigational weight-loss drug being studied in clinical trials for obesity and type 2 diabetes. It works by activating multiple appetite and metabolic hormone pathways at once, producing stronger weight loss than single-target drugs in early trials. Not FDA-approved; currently in Phase 2 clinical development.
The scientific side
Amycretin (now also designated zenagamtide) is a novel, single-molecule co-agonist that simultaneously activates GLP-1 receptors, amylin receptors (AMYR), and calcitonin receptors (CTR) (PMID 42532080; PMID 42532079; PMID 40550231). Its dual/tri-receptor engagement synergistically engages hindbrain-mediated satiety pathways and delays gastric emptying. In preclinical rodent studies, amycretin activated human, mouse, and rat GLP-1, amylin, and calcitonin receptors in cell-based systems; targeted key brain areas regulating food intake; reduced total energy intake by 47% in diet-induced obese (DIO) rats over 21 days; and improved insulin sensitivity and histological hallmarks of metabolic dysfunction-associated steatotic liver disease (MASLD). As a GLP-1 receptor agonist component, it promotes insulin secretion and suppresses glucagon; as an amylin/calcitonin receptor agonist, it induces satiety, suppresses prandial glucagon release, reduces prandial hyperglycaemia, and promotes weight loss through central mechanisms (PMID 41747885; PMID 41344603).
Class: Unimolecular GLP-1 and amylin receptor co-agonist (also calcitonin receptor agonist); incretin-based peptide therapeutic
Administration & storage
- Administration
- Subcutaneous injectiononce weekly (PMID: 40550231)Subcutaneous injectiononce weekly (PMID: 42532080)Oral tabletonce daily (PMID: 40550229)Oral tabletonce daily (PMID: 42532079)
- Storage
- No storage conditions for amycretin are described in the reviewed abstracts.
- Cautions
- Gastrointestinal adverse events (nausea, vomiting, constipation) are the most common treatment-emergent adverse events; they are dose-dependent and were reported to be mostly mild to moderate in severity, increasing in frequency with higher doses (PMID: 40550231; PMID: 40550229).,High-dose oral amycretin and CagriSema had higher GI adverse event rates than subcutaneous formulations in network meta-analysis; only high-dose CagriSema—not amycretin—significantly increased AE-related discontinuation in the same analysis, but data are described as preliminary.,Serious adverse events were reported in 8% of participants receiving subcutaneous zenagamtide across all dose groups in the phase 2 T2DM trial; no deaths occurred.,Serious adverse events were reported in 4% of participants receiving oral zenagamtide in the phase 2 T2DM trial; no deaths occurred.,Amycretin is an investigational agent without confirmed regulatory approval; use outside of clinical trials has not been evaluated for safety. Sterile technique is essential for any subcutaneous injection.
Legal & regulatory status
Not stated in reviewed literature — requires manual verification
Not stated in reviewed literature — requires manual verification
Not stated in reviewed literature — requires manual verification
What it's studied for
- Weight loss / anti-obesity (overweight and obesity without diabetes) Mixed
- Estimated mean bodyweight change from baseline was significantly greater with amycretin vs. placebo: Part B (60 mg, -24.3% vs -1.1%; week 36), Part C (20 mg, -22.0% vs 1.9%; week 36), Part D (5 mg, -16.2% vs 2.3%; week 28), Part E (1.25 mg, -9.7% vs 2.0%; week 20). Gastrointestinal adverse events were the most common t PMID 40550231 Dahl K et al. Lancet (2025). Phase 1b/2a RCT, subcutaneous amycretin, n=125, up to 36 weeks.
- Oral amycretin appeared safe and tolerable in people with overweight or obesity. Treatment-emergent adverse events were all mild or moderate; 49% were gastrointestinal. Pharmacodynamic weight-loss endpoints were exploratory. PMID 40550229 Gasiorek A et al. Lancet (2025). Phase 1, first-in-human, oral amycretin, n=144, up to 12 weeks.
- High-dose subcutaneous amycretin produced the largest percent body weight reduction vs. placebo (mean difference -23.95%; P score 1.00) among novel amylin-based therapies, exceeding semaglutide 2.4 mg (-11.45%) and liraglutide 3.0 mg (-6.4%). Oral amycretin had higher GI AE rates. PMID 42175595 Kamrul-Hasan et al. Endocrinology, Diabetes & Metabolism (2026). Network meta-analysis of 6 RCTs (N=4,642).
- Amycretin showed placebo-subtracted weight reduction of -23.9% (95% CI, -29.3% to -18.5%), numerically greater than commercially available agents including tirzepatide (-19.0%). PMID 42673585 Moiz A et al. Annals of Internal Medicine (2026). Systematic review of 38 RCTs (N=25,816).
- Glycemic control / type 2 diabetes Human RCT
- Once-weekly subcutaneous zenagamtide 0.4–40 mg demonstrated dose-dependent HbA1c reductions from -0.9% (0.4 mg) to -1.7% (40 mg) vs. placebo at week 36. Safety profile was consistent with GLP-1- and amylin-based therapies. No deaths occurred. PMID 42532080 Mora P et al. Lancet (2026). Phase 2 RCT, subcutaneous zenagamtide (amycretin), n=262, 36 weeks, T2DM.
- Once-daily oral zenagamtide at doses of 6, 25, and 50 mg produced HbA1c reductions of -0.9%, -1.3%, and -1.4% respectively vs. placebo at week 36, all statistically significant. GI adverse events were dose-dependent. No deaths occurred. PMID 42532079 Mora P et al. Lancet (2026). Phase 2 RCT, oral zenagamtide (amycretin), n=216, 36 weeks, T2DM.
- Metabolic dysfunction-associated steatotic liver disease (MASLD) Animal studies only
- Amycretin improved histological hallmarks of MASLD, primarily by reducing steatosis, in diet-induced obese rodents. PMID 40706446 Kuhre RE et al. EBioMedicine (2025). Preclinical studies in DIO mice and rats.
- Insulin resistance / insulin sensitivity improvement Animal studies only
- Insulin sensitivity improved significantly with amycretin administration in DIO rats compared with vehicle controls, as shown by higher glucose infusion rates during a hyperinsulinaemic euglycemic clamp. PMID 40706446 Kuhre RE et al. EBioMedicine (2025). Preclinical studies in DIO rats.
- Post-transplant diabetes mellitus (PTDM) — investigational mention In vitro only
- Amycretin is mentioned as a hypoglycemic drug still in clinical trials that may offer new opportunities for PTDM management, without specific trial data reported. PMID 39204092 Rudzki G et al. Pharmaceuticals (2024). Narrative review.
Safety signals
- Gastrointestinal adverse events (nausea, vomiting, constipation) — most common treatment-emergent adverse events; dose-dependent; predominantly mild to moderate in severity; increased in frequency at higher doses PMID 40550231
- Gastrointestinal adverse events — 49% of all treatment-emergent adverse events in phase 1 oral study; all adverse events mild or moderate; no deaths PMID 40550229
- Serious adverse events reported in 8% (21/261) of participants receiving subcutaneous zenagamtide across dose groups in 36-week phase 2 T2DM trial; no deaths PMID 42532080
- Serious adverse events reported in 4% (7/186) of participants receiving oral zenagamtide in 36-week phase 2 T2DM trial; no deaths PMID 42532079
- High GI adverse event rates (nausea, vomiting, constipation) more common with high-dose amycretin (both oral and subcutaneous) compared to placebo in network meta-analysis; findings described as preliminary and low-certainty PMID 42175595
- High proportion of study discontinuations observed in phase 1b/2a subcutaneous study, though a large proportion of discontinuations were reported as unrelated to treatment-emergent adverse events PMID 40550231
Contraindications
- No specific contraindications are explicitly stated in the reviewed abstracts. Phase 2 trials excluded adults outside BMI 23.0–<50.0 kg/m² and those not on stable metformin with or without SGLT2 inhibitor for T2DM studies; applicability outside these populations is not established. PMID 42532080
Protocol
No community protocol on record. In clinical studies, Amycretin (Zenagamtide) was dosed at Once-weekly subcutaneous: escalated from 0.3 mg up to maintenance doses of 60 mg (Part B), 20 mg (Part C), 5 mg (Part D), or 1.25 mg (Part E) Subcutaneous injection (PMID 40550231).
All studies (11)
- PMID 42532079 Human RCT
Glycemic control / type 2 diabetes - PMID 42532080 Human RCT
Glycemic control / type 2 diabetes - PMID 40550229 Mixed
Weight loss / anti-obesity (overweight and obesity without diabetes) - PMID 40550231 Mixed
Weight loss / anti-obesity (overweight and obesity without diabetes) - PMID 42175595 Mixed
Weight loss / anti-obesity (overweight and obesity without diabetes) - PMID 42673585 Mixed
Weight loss / anti-obesity (overweight and obesity without diabetes) - PMID 39204092 In vitro only
Post-transplant diabetes mellitus (PTDM) — investigational mention - PMID 40706446 Animal studies only
Metabolic dysfunction-associated steatotic liver disease (MASLD) - PMID 41344603
- PMID 41747885
- PMID 41850421
Frequently asked
What is amycretin and how does it work?
Amycretin (now also called zenagamtide) is a novel, single-molecule co-agonist that simultaneously activates GLP-1 receptors, amylin receptors, and calcitonin receptors (PMID 42532080; PMID 42532079). It was developed by Novo Nordisk. Its dual/tri-receptor engagement is proposed to synergistically engage satiety pathways in the hindbrain and delay gastric emptying. In preclinical rodent studies, it reduced energy intake, body weight, and improved insulin sensitivity and liver steatosis.
How much weight loss can amycretin cause?
In a phase 1b/2a randomised controlled study (subcutaneous administration, up to 36 weeks, participants with overweight or obesity), estimated mean bodyweight changes ranged from -9.7% (1.25 mg maintenance dose, 20 weeks) to -24.3% (60 mg maintenance dose, 36 weeks) versus small gains in the placebo group. A network meta-analysis ranked high-dose subcutaneous amycretin as producing the largest percent body weight reduction among novel amylin-based therapies (mean difference vs. placebo: -23.95%), exceeding semaglutide 2.4 mg (-11.45%) and liraglutide 3.0 mg (-6.4%), though findings are described as preliminary and based on sparse, low-certainty data. These are research findings; I'm not a medical professional and can't predict outcomes for any individual.
What dose of amycretin should I take?
I'm not a medical professional and can't recommend a protocol for you specifically. What research has shown: subcutaneous doses studied in clinical trials ranged from 0.4 mg to 60 mg once weekly, with escalation schedules starting as low as 0.2–0.3 mg (PMID 40550231; PMID 42532080). Oral doses studied ranged from 6 mg to 50 mg once daily, starting at 1.5 mg with escalation every 4 weeks (PMID 42532079; PMID 40550229). These are investigational doses from controlled research settings — amycretin is not an approved medication.
Is amycretin approved by the FDA?
The reviewed scientific literature does not explicitly state the current FDA approval status of amycretin/zenagamtide. As of the trials described (through 2026), it was in Phase 1 and Phase 2 clinical trials (PMID 40550231; PMID 42532080; PMID 42532079). Please consult the FDA website or a licensed healthcare provider for current regulatory status — requires manual verification.
What are the side effects of amycretin?
The most commonly reported adverse events in clinical trials are gastrointestinal in nature — including nausea, vomiting, and constipation — which are dose-dependent and mostly mild to moderate in severity (PMID 40550231; PMID 40550229). In the subcutaneous phase 2 trial in type 2 diabetes, serious adverse events occurred in 8% of amycretin participants; no deaths occurred. In the oral phase 2 trial, serious adverse events occurred in 4% of participants; no deaths occurred. A network meta-analysis found GI adverse events were more common with high-dose amycretin than placebo, but described findings as preliminary and low-certainty.
Can I combine amycretin with semaglutide or another GLP-1 drug?
I can't recommend combining compounds — that's a prescribing decision. Here's what has been studied individually: amycretin itself already contains a GLP-1 receptor agonist component within its single molecule. The reviewed abstracts do not contain clinical data on combining amycretin with semaglutide or other GLP-1 receptor agonists. One review discussed the strategic potential of combining amycretin with SGLT2 inhibitors theoretically, but no clinical trial data for such combinations were provided.
Is amycretin available in pill form?
Yes, an oral (tablet) formulation of amycretin (zenagamtide) has been investigated in clinical trials. A phase 1 first-in-human study tested once-daily oral amycretin at doses from 1 mg up to 2×50 mg (two tablets) in people with overweight or obesity. A phase 2 trial of oral zenagamtide at doses of 6, 25, and 50 mg once daily showed statistically significant HbA1c reductions vs. placebo over 36 weeks in people with type 2 diabetes. It is not commercially approved as of the literature reviewed.
Can amycretin treat type 2 diabetes?
Amycretin has been studied in people with type 2 diabetes in Phase 2 clinical trials. Once-weekly subcutaneous zenagamtide (0.4–40 mg) produced dose-dependent HbA1c reductions from -0.9% to -1.7% versus placebo over 36 weeks. Once-daily oral zenagamtide (6, 25, 50 mg) produced HbA1c reductions of -0.9%, -1.3%, and -1.4% vs. placebo over 36 weeks. These are investigational findings; amycretin is not an approved treatment for diabetes. Please consult a licensed healthcare provider for diabetes management.
Where can I buy amycretin?
I don't recommend vendors or sources. Please consult a licensed provider. Note that amycretin (zenagamtide) is an investigational drug studied in clinical trials funded by Novo Nordisk (PMID 40550231; PMID 42532080) and is not commercially approved based on the reviewed literature.
Is amycretin safe for people with kidney disease or after kidney transplant?
I can't suggest treatments for medical conditions. Please speak with a licensed healthcare provider. Regarding available evidence: one review mentioned amycretin among investigational hypoglycemic drugs that may offer new opportunities for post-transplant diabetes mellitus, but no clinical trial data specific to kidney transplant or kidney disease patients were provided in the reviewed literature. One review noted emerging evidence that long-acting amylin receptor agonists may show potential therapeutic benefits in diabetes-associated kidney complications, but this was not specific to amycretin in human trials.